Skip to contentM
Myriad Genetics Inc
M
MYGNMyriad Genetics Inc Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$209.80M$209.80Mderived−0.4% vs Q4 2024 Net Income-$7.90M-$7.90MderivedN/M vs Q4 2024 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Myriad Genetics Inc · CIK 899923 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$146,800,000−2.7% Operating Incomederived-$5,700,000N/M Operating Cash Flowderived$10,600,000+60.6% Margins · derivedGross margin70.0%−1.7 pt vs Q4 2024
Operating margin-2.7%+15.8 pt vs Q4 2024
Net margin-3.8%+16.4 pt vs Q4 2024
ended Dec 31, 2025 · filed Feb 24, 2026 · 55 d after period end